tradingkey.logo

Co-Diagnostics Inc

CODX
View Detailed Chart
2.360USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
113.62MMarket Cap
LossP/E TTM

Co-Diagnostics Inc

2.360
0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

0.00%

1 Month

-58.60%

6 Months

+838.37%

Year to Date

+1299.76%

1 Year

+246.70%

View Detailed Chart

TradingKey Stock Score of Co-Diagnostics Inc

Currency: USD Updated: 2026-01-13

Key Insights

Co-Diagnostics Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 120 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.50.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Co-Diagnostics Inc's Score

Industry at a Glance

Industry Ranking
120 / 208
Overall Ranking
308 / 4563
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Co-Diagnostics Inc Highlights

StrengthsRisks
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.92M.
Undervalued
The company’s latest PE is -2.42, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 375.84K shares, increasing 21.57% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 28.92K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.46.

Analyst Rating

Based on 2 analysts
Hold
Current Rating
30.000
Target Price
+1171.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Co-Diagnostics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Co-Diagnostics Inc Info

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Ticker SymbolCODX
CompanyCo-Diagnostics Inc
CEOEgan (Dwight H)
Websitehttps://codiagnostics.com/
KeyAI